This economic analysis published in The Lancet Diabetes & Endocrinology estimated that exposure to endocrine-disrupting chemicals costs the U.S. approximately $42 billion annually in healthcare expenses and lost productivity. The EU costs were estimated at 157 billion euros ($209 billion USD) per year.
The researchers calculated disease burden attributable to EDC exposure by combining epidemiological evidence with economic data. The conditions with the highest attributable costs included neurobehavioral disorders in children (including IQ loss and ADHD), obesity, diabetes, male reproductive disorders, and endometriosis.
The study highlighted that these costs represent a conservative estimate because they only accounted for conditions with the strongest epidemiological evidence.
Key Findings
- •Endocrine-disrupting chemical exposure costs the U.S. an estimated $42 billion annually in healthcare and lost productivity.
- •EU costs were estimated at 157 billion euros ($209 billion USD) per year.
- •Childhood neurobehavioral deficits including IQ loss represented the largest cost category.
- •Obesity, diabetes, and reproductive disorders were major contributors to the economic burden.
- •These estimates are conservative and likely underestimate the true societal cost.
Methodology
Systematic approach combining epidemiological evidence for causal relationships between EDC exposure and health outcomes, population-level exposure data, attributable fraction calculations, and economic modeling of healthcare costs and productivity losses. Expert panels assessed the strength of evidence for each EDC-disease pair using WHO/IPCS criteria.
Why This Matters for Families
This study puts a dollar figure on the societal cost of allowing endocrine-disrupting chemicals in our food supply. The $42 billion annual cost means taxpayers and families bear the financial burden of chemical industry profits. Investing in organic food and pesticide regulation is far cheaper than paying for the diseases these chemicals cause.
Original Source
/data

